Imaging of ankylosing spondylitis with PET-CT and MRI

• Conditions: Ankylosing spondylitis; Bechterew disease; 10023213

• Registration Number: NL-OMON35710
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

1. Diagnosis of ankylosing spondylitis according to the modified New York criteria
2. Treatment with disease modifying anti-rheumatic drugs (DMARDS), corticosteroids up to 10 mg daily and non-steroidal anti-inflammatory drugs (NSAIDs) is permitted, provided that there is a stable dose for at least 2 weeks.

Exclusion Criteria

1. Treatment with any investigational drug within the previous 3 months.
2. Pregnancy or breast-feeding.
3. Implanted pacemaker
4. Renal failure with creatinine clearance < 30 ml/min

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The uptake of the PET tracers F18-FDG and C11-(R)PK11195 (and, if applicable<br /><br>F18-Fluoride) in joints of the spine, SI joints and/or peripheral joints</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. Change of joint uptake of PET tracers after etanercept treatment<br /><br><br /><br>2. Signs of inflammation on MRI in spinal and/or SI joints (followed by<br /><br>comparison with PET tracer uptake) </p><br>